STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #192 by analyst upside · 2026-06-27
MREO
Mereo BioPharma Group plc
Healthcare · Market Cap $47M · P/E 0x
ANALYST PRICE TARGET
+473.7%
implied upside to consensus target
Current Price $0.3
Consensus Target $1.7
Bull Target $2.93
Bear Target $0.49
Analysts Covering 6
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
3
Hold
2
Sell
0
52-Week Low $0.2
52-Week High $3.05
YTD Return -41.8%
FUNDAMENTALS
Market Cap $47M
P/E Ratio (TTM) N/A
Forward P/E -7.9x
EPS (TTM) $-0.20
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.2
52-Week High $3.05
Current Price $0.3
Bear Target $0.49
Bull Target $2.93
● Now $0.3 ● Target $1.7
TRADING DATA
Avg Volume 3.4M
YTD Return -41.8%
Analyst Count 6
Consensus Buy
Upside to Target +473.7%
Last Updated 2026-06-27

ANALYST SUMMARY

Mereo BioPharma Group plc (MREO) is currently trading at $0.3 with a Wall Street consensus price target of $1.7, implying potential upside of 473.7% over the next 12 months. 6 analysts currently cover MREO, with a consensus rating of Buy - 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $2.93, while the most cautious has a target of $0.49.

MREO operates in the Healthcare sector with a market capitalisation of $47M. The stock is down 41.8% year-to-date and is currently trading near the lower end of its 52-week range of $0.2 – $3.05.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MREO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-05-12 38% win rate (8 calls)
JP Morgan ↓ Downgrade
Overweight → Neutral 2026-03-23 43% win rate (7 calls)
BTIG reit
Buy → Buy 2026-01-16 38% win rate (8 calls)
Needham — Reiterated
Buy → Buy 2026-01-13 20% win rate (5 calls)
Jefferies ↓ Downgrade
Buy → Hold 2025-12-30 50% win rate (6 calls)
BTIG — Reiterated
Buy → Buy 2025-12-29 38% win rate (8 calls)
LifeSci Capital ↓ Downgrade
Outperform → Market Perform 2025-12-29 Building track record
Needham reit
Buy → Buy 2025-12-22 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
29
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →